[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - cell.com
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

[引用][C] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - cir.nii.ac.jp

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - pubmed.ncbi.nlm.nih.gov
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - europepmc.org
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - Elsevier
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - cell.com
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

[HTML][HTML] The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - ncbi.nlm.nih.gov
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - paper.sciencenet.cn
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-
dependentkinases (CDKs) at discrete checkpoints during the transcription cycle. The …

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - research.monash.edu
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.

SJ Vervoort, SA Welsh, JR Devlin, E Barbieri… - Cell, 2021 - europepmc.org
Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent
kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing …